LCM
ESPR

Laurion Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Laurion Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,146
Closed -$48.9K – 537
2023
Q2 		$48.9K Buy
+35,146
New +$49.1K ﹤0.01% 565
2017
Q4 		– Sell
-10,800
Closed -$541K – 1608
2017
Q3 		$541K Buy
+10,800
New +$521K ﹤0.01% 1142
2015
Q3 		– Sell
-5,028
Closed -$411K – 779
2015
Q2 		$411K Buy
+5,028
New +$492K ﹤0.01% 488

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Laurion Capital Management's ESPR Position: Q3 2023 in Review

Laurion Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2023, closing a stake of 35,146 shares — an estimated $48.9K sold.

Laurion Capital Management first reported a position in ESPR in Q2 2015 and held it in 3 quarters. The position peaked at $541K in Q3 2017. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

  • Laurion Capital Management reported no remaining Esperion Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 35,146 Esperion Therapeutics shares in Q3 2023, an estimated $48.9K.
  • Laurion Capital Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 3 quarters.
  • Laurion Capital Management's Esperion Therapeutics position peaked at $541K in Q3 2017.
  • 122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.